Alnylam Pharmaceuticals is projecting substantial revenue growth in 2025, fueled by its expanding portfolio of RNAi therapeutics. The company anticipates net product revenues to reach between $2.05 billion and $2.25 billion, representing a 31% increase compared to 2024. This growth is expected to be driven by strong performance in both its transthyretin (TTR) and rare disease franchises.
Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam, stated, "Alnylam’s commercial and clinical achievements in 2024 position us very well for another transformative year in 2025, as we continue to evolve into a global, top-tier biotech company." She highlighted the potential launch of vutrisiran in ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a key driver of topline growth.
Financial Performance and Guidance
Alnylam reported preliminary full-year 2024 net product revenues of $1.646 billion for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, marking a 33% increase compared to 2023. The company's 2025 revenue guidance anticipates continued growth across its key products:
- Total TTR (ONPATTRO, AMVUTTRA (PN & CM)): $1.60 billion to $1.725 billion, representing 36% growth compared to 2024.
- Total Rare (GIVLAARI, OXLUMO): $450 million to $525 million, representing 15% growth compared to 2024.
Alnylam also expects to achieve non-GAAP operating income profitability in 2025, a significant milestone for the company.
Pipeline Advancements
Alnylam is making significant strides in its clinical pipeline. Key goals for 2025 include:
- Vutrisiran: Anticipated FDA approval for ATTR-CM by the PDUFA target action date of March 23, 2025, with additional global approvals expected in the second half of the year.
- Nucresiran (ALN-TTRsc04): Initiation of a Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy in the first half of 2025.
- Zilebesiran: Reporting results from the KARDIA-3 Phase 2 study in hypertension in the second half of 2025 and initiating a Phase 3 cardiovascular outcomes trial.
- Mivelsiran: Reporting interim results from Part B of the Phase 1 study in Alzheimer’s disease and initiating a Phase 2 study in Alzheimer’s disease in the second half of 2025.
- ALN-6400: Initiation of a Phase 2 study in a bleeding disorder in the second half of 2025.
Additionally, Alnylam plans to file Investigational New Drug (IND) applications for four new Alnylam-led programs by the end of 2025.
Partnered Programs
Alnylam's partnered programs are also progressing, including:
- Fitusiran (with Sanofi): Anticipated FDA approval for hemophilia A and B by the PDUFA target action date of March 28, 2025.
- Elebsiran (with Vir Biotechnology): Expected initiation of a Phase 3 chronic hepatitis delta registrational study and reporting of functional cure results from a Phase 2 chronic hepatitis B study.
RNAi Therapeutics
Alnylam has been at the forefront of RNAi therapeutics, a novel approach to drug development that harnesses the natural cellular process of gene silencing. By targeting messenger RNA (mRNA), RNAi therapeutics can prevent the production of disease-causing proteins. Alnylam's commercial RNAi therapeutic products include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran).
